CD8 T cell help for innate antitumor immunity

Journal of Immunology

Volumn 179, Issue 10, 2007, Pages 6651-6662

  Shanker, Anil ^a,b,c,d   Verdeil, Grégory ^a,b,c   Buferne, Michel ^a,b,c   Inderberg Suso, Else Marit ^a,b,c   Puthier, Denis ^b   Joly, Florence ^b   Nguyen, Catherine ^b   Leserman, Lee ^a,b,c   Auphan Anezin, Nathalie ^a,b,c   Schmitt Verhulst, Anne Marie ^a,b,c  

^a CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^b INSERM   (France)

^c CNRS   (France)

^d SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GENE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CONTROLLED STUDY; GENE EXPRESSION PROFILING; INNATE IMMUNITY; MAST CELL; MASTOCYTOMA; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TUMOR CELL; TUMOR ESCAPE; TUMOR IMMUNITY; ANIMAL; CANCER TRANSPLANTATION; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; GRAFT REJECTION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE MUTANT; SARCOMA;

CANCER TESTIS ANTIGEN P1A, MOUSE; CANCER-TESTIS ANTIGEN P1A, MOUSE; HOMEODOMAIN PROTEIN; RAG 1 PROTEIN; RAG-1 PROTEIN; TUMOR ANTIGEN; TUMOR REJECTION ANTIGEN P815A, MOUSE; UNCLASSIFIED DRUG;

ANIMALS; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GRAFT REJECTION; HOMEODOMAIN PROTEINS; IMMUNITY, NATURAL; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MAST-CELL SARCOMA; MICE; MICE, MUTANT STRAINS; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TUMOR ESCAPE;

EID: 38449096756     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.10.6651     Document Type: Article

References (66)

1. Dunn, G. P., A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3: 991-998.
2. Shankaran, V., H. Ikeda, A. T. Bruce, J. M. White, P. E. Swanson, L. J. Old, and R. D. Schreiber. 2001. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111.
3. Medzhitov, R., and C. A. Janeway, Jr. 2002. Decoding the patterns of self and nonself by the innate immune system. Science 296: 298-300.
4. Glas, R., L. Franksson, C. Une, M. L. Eloranta, C. Ohlen, A. Orn, and K. Karre. 2000. Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype: an adaptive component of NK cell-mediated responses. J. Exp. Med. 191: 129-138.
5. low targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 19: 561-569.
6. Kelly, J. M., P. K. Darcy, J. L. Markby, D. I. Godfrey, K. Takeda, H. Yagita, and M. J. Smyth. 2002. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat. Immunol. 3: 83-90.
7. Coulie, P. G., H. Ikeda, J. F. Baurain, and R. Chiari. 1999. Antitumor immunity at work in a melanoma patient. Adv. Cancer Res. 76: 213-242.
8. 2- microglobulin transfection to EL-4 mutant cells. J. Exp. Med. 175: 843-846.
9. Lanier, L. L. 1998. NK cell receptors. Annu. Rev. Immunol. 16: 359-393.
10. Long, E. O. 1999. Regulation of immune responses through inhibitory receptors. Annu. Rev. Immunol. 17: 875-904.
11. Moretta, A., C. Bottino, M. Vitale, D. Pende, C. Cantoni, M. C. Mingari, R. Biassoni, and L. Moretta. 2001. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19: 197-223.
12. Jamieson, A. M., A. Diefenbach, C. W. McMahon, N. Xiong, J. R. Carlyle, and D. H. Raulet. 2002. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17: 19-29.
13. Groh, V., A. Steinle, S. Bauer, and T. Spies. 1998. Recognition of stress-induced MHC molecules by intestinal epithelial γδ T cells. Science 279: 1737-1740.
14. Gasser, S., S. Orsulic, E. J. Brown, and D. H. Raulet. 2005. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436: 1186-1190.
15. Cerwenka, A., J. L. Baron, and L. L. Lanier. 2001. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. USA 98: 11521-11526.
16. Diefenbach, A., E. R. Jensen, A. M. Jamieson, and D. H. Raulet. 2001. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413: 165-171.
17. Van Der Bruggen, P., Y. Zhang, P. Chaux, V. Stroobant, C. Panichelli, E. S. Schultz, J. Chapiro, B. J. Van Den Eynde, F. Brasseur, and T. Boon. 2002. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev. 188: 51-64.
18. Lethe, B., B. van den Eynde, A. van Pel, G. Corradin, and T. Boon. 1992. Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. Eur. J. Immunol. 22: 2283-2288.
19. Brandle, D., J. Bilsborough, T. Rulicke, C. Uyttenhove, T. Boon, and B. J. Van den Eynde. 1998. The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection. Eur. J. Immunol. 28: 4010-4019.
20. Van den Eynde, B., H. Mazarguil, B. Lethe, F. Laval, and J. E. Gairin. 1994. Localization of two cytotoxic T lymphocyte epitopes and three anchoring residues on a single nonameric peptide that binds to H-2Ld and is recognized by cytotoxic T lymphocytes against mouse tumor P815. Eur. J. Immunol. 24: 2740-2745.
21. Uyttenhove, C., J. Maryanski, and T. Boon. 1983. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med. 157: 1040-1052.
22. Bai, X. F., J. Liu, O. Li, P. Zheng, and Y. Liu. 2003. Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes. J. Clin. Invest. 111: 1487-1496.
23. Bilsborough, J., A. Van Pel, C. Uyttenhove, T. Boon, and B. J. Van den Eynde. 1999. Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815. J. Immunol. 162: 3534-3540.
24. Shanker, A., N. Auphan-Anezin, P. Chomez, L. Giraudo, B. Van den Eynde, and A. M. Schmitt-Verhulst. 2004. Thymocyte-intrinsic genetic factors influence CD8 T cell lineage commitment and affect selection of a tumor-reactive TCR. J. Immunol. 172: 5069-5077.
25. Brichard, V. G., G. Warnier, A. Van Pel, G. Morlighem, S. Lucas, and T. Boon. 1995. Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815. Eur. J. Immunol. 25: 664-671.
26. Alter, G., J. M. Malenfant, and M. Altfeld. 2004. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 294: 15-22.
27. Lyons, A. B., and C. R. Parish. 1994. Determination of lymphocyte division by flow cytometry. J. Immunol. Methods 171: 131-137.
28. Koo, G. C., and J. R. Peppard. 1984. Establishment of monoclonal anti-Nk-1.1 antibody. Hybridoma 3: 301-303.
29. Puthier, D., F. Joly, M. Irla, M. Saade, G. Victorero, B. Loriod, and C. Nguyen. 2004. A general survey of thymocyte differentiation by transcriptional analysis of knockout mouse models. J. Immunol. 173: 6109-6118.
30. Baugh, L. R., A. A. Hill, E. L. Brown, and C. P. Hunter. 2001. Quantitative analysis of mRNA amplification by in vitro transcription. Nucleic Acids Res. 29: E29.
31. Verdeil, G., D. Puthier, C. Nguyen, A. M. Schmitt-Verhulst, and N. Auphan-Anezin. 2002. Gene profiling approach to establish the molecular bases for partial versus full activation of naive CD8 T lymphocytes. Ann. NY Acad. Sci. 975: 68-76.
32. Lopez, F., J. Rougemont, B. Loriod, A. Bourgeois, L. Loi, F. Bertucci, P. Hingamp, R. Houlgatte, and S. Granjeaud. 2004. Feature extraction and signal processing for nylon DNA microarrays. BMC Genomics 5: 38.
33. Verdeil, G., D. Puthier, C. Nguyen, A. M. Schmitt-Verhulst, and N. Auphan-Anezin. 2006. STAT5-mediated signals sustain a TCR-initiated gene expression program toward differentiation of CD8 T cell effectors. J. Immunol. 176: 4834-4842.
34. + T cells responding to infection. J. Immunol. 174: 6791-6802.
35. Zhang, B., N. A. Bowerman, J. K. Salama, H. Schmidt, M. T. Spiotto, A. Schietinger, P. Yu, Y. X. Fu, R. R. Weichselbaum, D. A. Rowley, et al. 2007. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J. Exp. Med. 204: 49-55.
36. Wang, M., C. A. Ellison, J. G. Gartner, and K. T. HayGlass. 1998. Natural killer cell depletion fails to influence initial CD4 T cell commitment in vivo in exogenous antigen-stimulated cytokine and antibody responses. J. Immunol. 160: 1098-1105.
37. Vinay, D. S., B. K. Choi, J. S. Bae, W. Y. Kim, B. M. Gebhardt, and B. S. Kwon. 2004. CD137-deficient mice have reduced NK/NKT cell numbers and function, are resistant to lipopolysaccharide-induced shock syndromes, and have lower IL-4 responses. J. Immunol. 173: 4218-4229.
38. Salazar-Mather, T. P., J. S. Orange, and C. A. Biron. 1998. Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1α (MIP-1α)-dependent pathways. J. Exp. Med. 187: 1-14.
39. Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21: 137-148.
40. Smyth, M. J., D. I. Godfrey, and J. A. Trapani. 2001. A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol. 2: 293-299.
41. Zippelius, A., P. Batard, V. Rubio-Godoy, G. Bioley, D. Lienard, F. Lejeune, D. Rimoldi, P. Guillaume, N. Meidenbauer, A. Mackensen, et al. 2004. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 64: 2865-2873.
42. + T cell responses against human tumor antigens. J. Immunol. 172: 5363-5370.
43. + T cell adoptive immunotherapy. Immunity 13: 265-276.
44. Matsui, K., L. A. O'Mara, and P. M. Allen. 2003. Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy. Int. Immunol. 15: 797-805.
45. Dudley, M. E., and D. C. Roopenian. 1996. Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens. J. Exp. Med. 184: 441-447.
46. + T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice. Eur. J. Immunol. 33: 556-566.
47. Bai, X. F., J. Q. Liu, P. S. Joshi, L. Wang, L. Yin, J. Labanowska, N. Heerema, P. Zheng, and Y. Liu. 2006. Different lineages of P1A-expressing cancer cells use divergent modes of immune evasion for T-cell adoptive therapy. Cancer Res. 66: 8241-8249.
48. Blankenstein, T. 2005. The role of tumor stroma in the interaction between tumor and immune system. Curr. Opin. Immunol. 17: 180-186.
49. Spiotto, M. T., D. A. Rowley, and H. Schreiber. 2004. Bystander elimination of antigen loss variants in established tumors. Nat. Med. 10: 294-298.
50. Chan, C. W., E. Crafton, H. N. Fan, J. Flook, K. Yoshimura, M. Skarica, D. Brockstedt, T. W. Dubensky, M. F. Stins, L. L. Lanier, et al. 2006. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat. Med. 12: 207-213.
51. Taieb, J., N. Chaput, C. Menard, L. Apetoh, E. Ullrich, M. Bonmort, M. Pequignot, N. Casares, M. Terme, C. Flament, et al. 2006. A novel dendritic cell subset involved in tumor immunosurveillance. Nat. Med. 12: 214-219.
52. Morris, M. A., and K. Ley. 2004. Trafficking of natural killer cells. Curr. Mol. Med. 4: 431-438.
53. Zibert, A., S. Balzer, M. Souquet, T. H. Quang, C. Paris-Scholz, M. Roskrow, and D. Dilloo. 2004. CCL3/MIP-1α is a potent immunostimulator when coexpressed with interleukin-2 or granulocyte-macrophage colony-stimulating factor in a leukemia/lymphoma vaccine. Hum. Gene Ther. 15: 21-34.
54. Smyth, M. J., E. Cretney, K. Takeda, R. H. Wiltrout, L. M. Sedger, N. Kayagaki, H. Yagita, and K. Okumura. 2001. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon γ-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 193: 661-670.
55. Hayakawa, Y., N. D. Huntington, S. L. Nutt, and M. J. Smyth. 2006. Functional subsets of mouse natural killer cells. Immunol. Rev. 214: 47-55.
56. Xu, J., A. K. Chakrabarti, J. L. Tan, L. Ge, A. Gambotto, and N. L. Vujanovic. 2007. Essential role of the TNF-TNFR2 cognate interaction in mouse dendritic cell-natural killer cell cross-talk. Blood 109: 3333-3341.
57. Fernandez, N. C., A. Lozier, C. Flament, P. Ricciardi-Castagnoli, D. Bellet, M. Suter, M. Perricaudet, T. Tursz, E. Maraskovsky, and L. Zitvogel. 1999. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat. Med. 5: 405-411.
58. Wilson, J. L., J. Charo, A. Martin-Fontecha, P. Dellabona, G. Casorati, B. J. Chambers, R. Kiessling, M. T. Bejarano, and H. G. Ljunggren. 1999. NK cell triggering by the human costimulatory molecules CD80 and CD86. J. Immunol. 163: 4207-4212.
59. Keefe, D., L. Shi, S. Feske, R. Massol, F. Navarro, T. Kirchhausen, and J. Lieberman. 2005. Perforin triggers a plasma membrane-repair response that facilitates CTL induction of apoptosis. Immunity 23: 249-262.
60. Kandil, H., V. Bachy, D. J. Williams, R. Helmi, F. M. Gotch, and M. A. Ibrahim. 2005. Regulation of dendritic cell interleukin-12 secretion by tumour cell necrosis. Clin. Exp. Immunol. 140: 54-64.
61. Chiesa, S., M. Mingueneau, N. Fuseri, B. Malissen, D. H. Raulet, M. Malissen, E. Vivier, and E. Tomasello. 2006. Multiplicity and plasticity of natural killer cell signaling pathways. Blood 107: 2364-2372.
62. Hanna, J., P. Bechtel, Y. Zhai, F. Youssef, K. McLachlan, and O. Mandelboim. 2004. Novel insights on human NK cells' immunological modalities revealed by gene expression profiling. J. Immunol. 173: 6547-6563.
63. Kayagaki, N., N. Yamaguchi, M. Nakayama, K. Takeda, H. Akiba, H. Tsutsui, H. Okamura, K. Nakanishi, K. Okumura, and H. Yagita. 1999. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J. Immunol. 163: 1906-1913.
64. Vermijlen, D., D. Luo, C. J. Froelich, J. P. Medema, J. A. Kummer, E. Willems, F. Braet, and E. Wisse. 2002. Hepatic natural killer cells exclusively kill splenic/blood natural killer-resistant tumor cells by the perforin/granzyme pathway. J. Leukocyte Biol. 72: 668-676.
65. Vermijlen, D., C. Seynaeve, D. Luo, M. Kruhoffer, D. L. Eizirik, T. F. Orntoft, and E. Wisse. 2004. High-density oligonucleotide array analysis reveals extensive differences between freshly isolated blood and hepatic natural killer cells. Eur. J. Immunol. 34: 2529-2540.
66. Robertson, M. J. 2002. Role of chemokines in the biology of natural killer cells. J. Leukocyte Biol. 71: 173-183.